ANDA 202039, held by Aurobindo Pharma. Fexofenadine Hydrochloride.
As of Nov 21, 2026, ANDA 202039 (Children's Fexofenadine Hydrochloride Allergy, Fexofenadine Hydrochloride Allergy), held by Aurobindo Pharma, was first approved by FDA on Nov 19, 2014, with 1 approved supplement and 0 published complete response letters.
Uses temporarily relieves these symptoms due to hay fever or other upper respiratory allergies: runny nose itchy, watery eyes sneezing itching of the nose or throat
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 19, 2014 | Original application | Approved | None posted |
| Children's Fexofenadine Hydrochloride Allergy30MG · tablet;oral | Fexofenadine Hydrochloride | OTC |
| Fexofenadine Hydrochloride Allergy60MG · tablet;oral | Fexofenadine Hydrochloride | OTC |
| Fexofenadine Hydrochloride Allergy180MG · tablet;oral | Fexofenadine Hydrochloride | OTC |
| Sep 15, 2017 | Supplement 3Manufacturing | Approved | None posted |
| Nov 19, 2014 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters